mitotane has been researched along with Hypogonadism in 2 studies
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
Hypogonadism: Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied." | 8.31 | Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study. ( Alberti, A; Berruti, A; Cappelli, C; Cosentini, D; Cremaschi, V; Delbarba, A; Facondo, P; Ferlin, A; Grisanti, S; Laganà, M; Pezzaioli, LC, 2023) |
| "Mitotane is a drug which is concentrated largely in adipose tissue and the adrenal glands." | 5.27 | Primary hypogonadism associated with o,p' DDD (mitotane) therapy. ( Sparagana, M, 1987) |
| "Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied." | 4.31 | Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study. ( Alberti, A; Berruti, A; Cappelli, C; Cosentini, D; Cremaschi, V; Delbarba, A; Facondo, P; Ferlin, A; Grisanti, S; Laganà, M; Pezzaioli, LC, 2023) |
| "Mitotane is a drug which is concentrated largely in adipose tissue and the adrenal glands." | 1.27 | Primary hypogonadism associated with o,p' DDD (mitotane) therapy. ( Sparagana, M, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delbarba, A | 1 |
| Cosentini, D | 1 |
| Facondo, P | 1 |
| Laganà, M | 1 |
| Pezzaioli, LC | 1 |
| Cremaschi, V | 1 |
| Alberti, A | 1 |
| Grisanti, S | 1 |
| Cappelli, C | 1 |
| Ferlin, A | 1 |
| Berruti, A | 1 |
| Sparagana, M | 1 |
2 other studies available for mitotane and Hypogonadism
| Article | Year |
|---|---|
Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Androgens; Humans; Hypogonadism; Longitudinal St | 2023 |
Primary hypogonadism associated with o,p' DDD (mitotane) therapy.
Topics: ACTH Syndrome, Ectopic; Adult; Erectile Dysfunction; Gonadotropins; Humans; Hypogonadism; Luteinizin | 1987 |